Deep learning-based subtyping of gastric cancer histology predicts clinical outcome: a multi-institutional retrospective study

Gregory Patrick Veldhuizen, Christoph Roecken, Hans-Michael Behrens, Didem Cifci, Hannah Sophie Muti, Takaki Yoshikawa, Tomio Arai, Takashi Oshima, Patrick Tan, Matthias P. Ebert, Alexander T. Pearson, Julien Calderaro, Heike I. Grabsch, Jakob Nikolas Kather*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction The Lauren classification is widely used for Gastric Cancer (GC) histology subtyping. However, this classification is prone to interobserver variability and its prognostic value remains controversial. Deep Learning ( DL)-based assessment of hematoxylin and eosin (H&E) stained slides is a potentially useful tool to provide an additional layer of clinically relevant information, but has not been systematically assessed in GC. Objective We aimed to train, test and externally validate a deep learning-based classifier for GC histology subtyping using routine H&E stained tissue sections from gastric adenocarcinomas and to assess its potential prognostic utility. Methods We trained a binary classifier on intestinal and diffuse type GC whole slide images for a subset of the TCGA cohort (N = 166) using attention-based multiple instance learning. The ground truth of 166 GC was obtained by two expert pathologists. We deployed the model on two external GC patient cohorts, one from Europe (N = 322) and one from Japan (N = 243). We assessed classification performance using the Area Under the Receiver Operating Characteristic Curve (AUROC) and prognostic value (overall, cancer specific and disease free survival) of the DL-based classifier with uni- and multivariate Cox proportional hazard models and Kaplan-Meier curves with log-rank test statistics. Results Internal validation using the TCGA GC cohort using five- fold cross-validation achieved a mean AUROC of 0.93 +/- 0.07. External validation showed that the DL-based classifier can better stratify GC patients' 5-year survival compared to pathologist-based Lauren classification for all survival endpoints, despite frequently divergent model-pathologist classifications. Univariate overall survival Hazard Ratios (HRs) of pathologist- based Lauren classification (diffuse type versus intestinal type) were 1.14 (95% Confidence Interval (CI) 0.66-1.44, p-value = 0.51) and 1.23 (95% CI 0.96-1.43, p-value = 0.09) in the Japanese and European cohorts, respectively. DL-based histology classification resulted in HR of 1.46 (95% CI 1.18-1.65, p-value < 0.005) and 1.41 (95% CI 1.20-1.57, p-value < 0.005), in the Japanese and European cohorts, respectively. In diffuse type GC (as defined by the pathologist), classifying patients using the DL diffuse and intestinal classifications provided a superior survival stratification, and demonstrated statistically significant survival stratification when combined with pathologist classification for both the Asian ( overall survival log-rank test p-value < 0.005, HR 1.43 (95% CI 1.05-1.66, p-value = 0.03) and European cohorts (overall survival log-rank test p-value < 0.005, HR 1.56 (95% CI 1.16-1.76, p-value < 0.005)). Conclusion Our study shows that gastric adenocarcinoma subtyping using pathologist's Lauren classification as ground truth can be performed using current state of the art DL techniques. Patient survival stratification seems to be better by DL-based histology typing compared with expert pathologist histology typing. DL-based GC histology typing has potential as an aid in subtyping. Further investigations are warranted to fully understand the underlying biological mechanisms for the improved survival stratification despite apparent imperfect classification by the DL algorithm.
Original languageEnglish
Pages (from-to)708-720
Number of pages13
JournalGastric Cancer
Volume26
Issue number5
Early online dateJun 2023
DOIs
Publication statusPublished - 1 Jun 2023

Keywords

  • Gastric cancer histology
  • Lauren classification
  • Deep learning classifier
  • Prognostic utility
  • Survival stratification
  • Hematoxylin
  • Eosin staining
  • SURVIVAL
  • HETEROGENEITY
  • CARCINOMA

Cite this